We are analyzing https://link.springer.com/article/10.1007/s10067-019-04578-2.

Title:
Efficacy of rituximab in resistant palindromic rheumatism: first report in literature | Clinical Rheumatology
Description:
Rituximab (RTX) provides significant clinical benefits in active rheumatoid arthritis (RA) patients with inadequate response to DMARDs and anti-TNF. There is no data regarding efficacy of RTX in seropositive Palindromic Rheumatism (PR), a forerunner of RA. To determine the efficacy and safety of RTX treatment in active PR patients exhibiting inadequate response to conventional synthetic DMARDs (csDMARDs). The retrospective study, over a period of 3 years, included seropositive (RF ± antiCCP) PR patients with inadequate control of PR (> 4 attacks per months) despite combination csDMARDs and were treated with RTX. All the patients were treated with an initial dose of 500 mg RTX and later with a second infusion after 2 weeks’ period in those who did not achieve adequate/ complete disease control. Patients were continued on csDMARDS and retreated with RTX on relapse of symptoms. Thirty-three seropositive PR patients with a mean age of 48.15 ± 14.2 years, mean disease duration of 68.4 ± 68.2 months, mean follow up period of 24.3 ± 10.8 months, were treated with RTX. 88% patients were on combination DMARDS and 79% patients were females. All patient achieved rapid and complete control of palindromic attacks with RTX. Fifteen patients had a relapse after a mean duration of 10.4 ± 5.5 months and needed repeat RTX infusions following which remission was achieved. None of the patients progressed to RA till the end of the follow-up. No serious adverse effects were recorded. RTX treatment could be effective in achieving disease control in active palindromic rheumatism not responding to csDMARDs. • PR is thought to be a forerunner of RA and rituximab (RTX) has been found to be effective in RA. • Our study supports the hypothesis that B cells play an important role in the pathophysiology of PR and that the combination (RTX+ conventional drugs) can prevent the disease evolution into RA. • This 3-year retrospective study showed that rituximab was found to be effective in those who responded poorly to conventional drugs and remission was achieved in all patients. • Although it is a rare disease, we see palindromic rheumatism patients in India more often. As the symptoms are very debilitating in these patients, in those patients, not controlled on conventional drugs, rituximab offers newer promise in controlling the attacks and prevents further progression to RA.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

patients, article, palindromic, rheumatism, rituximab, arthritis, google, scholar, rtx, rheumatoid, pubmed, rheumatol, cas, clinical, study, privacy, cookies, content, efficacy, active, csdmards, disease, access, data, information, publish, search, response, conventional, control, months, treated, springer, log, journal, research, rheumatology, published, raghavan, sreenath, cherian, padmanabha, shenoy, inadequate, dmards, seropositive, treatment, period, attacks, combination,

Topics {✒️}

month download article/chapter b-cell–targeted therapy active rheumatoid arthritis full article pdf privacy choices/manage cookies related subjects active palindromic rheumatism serum complement study additional information publisher rheumatoid arthritis significant clinical benefits european economic area previous bdmards failures gamez-nava ji connective tissue diseases progressive joint damage ethics declarations disclosures article raghavan achieving disease control conditions privacy policy resistant palindromic rheumatism van vollenhoven rf seropositive palindromic rheumatism accepting optional cookies somy cherian & padmanabha patient achieved rapid article log main content log check access instant access palindromic rheumatism patients conventional synthetic dmards journal finder publish palindromic rheumatism treated article cite author correspondence seropositive pr patients rtx+ conventional drugs retrospective study complete control inadequate control year results 2-year results rituximab therapy inadequate response privacy policy palindromic rheumatism study supports interventional study books a

Questions {❓}

Mankia K, Emery P (2017) What can palindromic rheumatism tell us?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Efficacy of rituximab in resistant palindromic rheumatism: first report in literature
         description:Rituximab (RTX) provides significant clinical benefits in active rheumatoid arthritis (RA) patients with inadequate response to DMARDs and anti-TNF. There is no data regarding efficacy of RTX in seropositive Palindromic Rheumatism (PR), a forerunner of RA. To determine the efficacy and safety of RTX treatment in active PR patients exhibiting inadequate response to conventional synthetic DMARDs (csDMARDs). The retrospective study, over a period of 3 years, included seropositive (RF ± antiCCP) PR patients with inadequate control of PR (> 4 attacks per months) despite combination csDMARDs and were treated with RTX. All the patients were treated with an initial dose of 500 mg RTX and later with a second infusion after 2 weeks’ period in those who did not achieve adequate/ complete disease control. Patients were continued on csDMARDS and retreated with RTX on relapse of symptoms. Thirty-three seropositive PR patients with a mean age of 48.15 ± 14.2 years, mean disease duration of 68.4 ± 68.2 months, mean follow up period of 24.3 ± 10.8 months, were treated with RTX. 88% patients were on combination DMARDS and 79% patients were females. All patient achieved rapid and complete control of palindromic attacks with RTX. Fifteen patients had a relapse after a mean duration of 10.4 ± 5.5 months and needed repeat RTX infusions following which remission was achieved. None of the patients progressed to RA till the end of the follow-up. No serious adverse effects were recorded. RTX treatment could be effective in achieving disease control in active palindromic rheumatism not responding to csDMARDs. • PR is thought to be a forerunner of RA and rituximab (RTX) has been found to be effective in RA. • Our study supports the hypothesis that B cells play an important role in the pathophysiology of PR and that the combination (RTX+ conventional drugs) can prevent the disease evolution into RA. • This 3-year retrospective study showed that rituximab was found to be effective in those who responded poorly to conventional drugs and remission was achieved in all patients. • Although it is a rare disease, we see palindromic rheumatism patients in India more often. As the symptoms are very debilitating in these patients, in those patients, not controlled on conventional drugs, rituximab offers newer promise in controlling the attacks and prevents further progression to RA.
         datePublished:2019-05-10T00:00:00Z
         dateModified:2019-05-10T00:00:00Z
         pageStart:2399
         pageEnd:2402
         sameAs:https://doi.org/10.1007/s10067-019-04578-2
         keywords:
            csDMARDs
            Palindromic rheumatism
            Rheumatoid arthritis
            Rituximab
            Rheumatology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10067-019-04578-2/MediaObjects/10067_2019_4578_Fig1_HTML.png
         isPartOf:
            name:Clinical Rheumatology
            issn:
               1434-9949
               0770-3198
            volumeNumber:38
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer London
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Padmaja Raghavan
               affiliation:
                     name:Centre for Arthritis & Rheumatism Excellence (CARE)
                     address:
                        name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sreelakshmi Sreenath
               affiliation:
                     name:Centre for Arthritis & Rheumatism Excellence (CARE)
                     address:
                        name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Somy Cherian
               affiliation:
                     name:Centre for Arthritis & Rheumatism Excellence (CARE)
                     address:
                        name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Padmanabha D. Shenoy
               url:http://orcid.org/0000-0002-7666-1361
               affiliation:
                     name:Centre for Arthritis & Rheumatism Excellence (CARE)
                     address:
                        name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Efficacy of rituximab in resistant palindromic rheumatism: first report in literature
      description:Rituximab (RTX) provides significant clinical benefits in active rheumatoid arthritis (RA) patients with inadequate response to DMARDs and anti-TNF. There is no data regarding efficacy of RTX in seropositive Palindromic Rheumatism (PR), a forerunner of RA. To determine the efficacy and safety of RTX treatment in active PR patients exhibiting inadequate response to conventional synthetic DMARDs (csDMARDs). The retrospective study, over a period of 3 years, included seropositive (RF ± antiCCP) PR patients with inadequate control of PR (> 4 attacks per months) despite combination csDMARDs and were treated with RTX. All the patients were treated with an initial dose of 500 mg RTX and later with a second infusion after 2 weeks’ period in those who did not achieve adequate/ complete disease control. Patients were continued on csDMARDS and retreated with RTX on relapse of symptoms. Thirty-three seropositive PR patients with a mean age of 48.15 ± 14.2 years, mean disease duration of 68.4 ± 68.2 months, mean follow up period of 24.3 ± 10.8 months, were treated with RTX. 88% patients were on combination DMARDS and 79% patients were females. All patient achieved rapid and complete control of palindromic attacks with RTX. Fifteen patients had a relapse after a mean duration of 10.4 ± 5.5 months and needed repeat RTX infusions following which remission was achieved. None of the patients progressed to RA till the end of the follow-up. No serious adverse effects were recorded. RTX treatment could be effective in achieving disease control in active palindromic rheumatism not responding to csDMARDs. • PR is thought to be a forerunner of RA and rituximab (RTX) has been found to be effective in RA. • Our study supports the hypothesis that B cells play an important role in the pathophysiology of PR and that the combination (RTX+ conventional drugs) can prevent the disease evolution into RA. • This 3-year retrospective study showed that rituximab was found to be effective in those who responded poorly to conventional drugs and remission was achieved in all patients. • Although it is a rare disease, we see palindromic rheumatism patients in India more often. As the symptoms are very debilitating in these patients, in those patients, not controlled on conventional drugs, rituximab offers newer promise in controlling the attacks and prevents further progression to RA.
      datePublished:2019-05-10T00:00:00Z
      dateModified:2019-05-10T00:00:00Z
      pageStart:2399
      pageEnd:2402
      sameAs:https://doi.org/10.1007/s10067-019-04578-2
      keywords:
         csDMARDs
         Palindromic rheumatism
         Rheumatoid arthritis
         Rituximab
         Rheumatology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10067-019-04578-2/MediaObjects/10067_2019_4578_Fig1_HTML.png
      isPartOf:
         name:Clinical Rheumatology
         issn:
            1434-9949
            0770-3198
         volumeNumber:38
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer London
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Padmaja Raghavan
            affiliation:
                  name:Centre for Arthritis & Rheumatism Excellence (CARE)
                  address:
                     name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sreelakshmi Sreenath
            affiliation:
                  name:Centre for Arthritis & Rheumatism Excellence (CARE)
                  address:
                     name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Somy Cherian
            affiliation:
                  name:Centre for Arthritis & Rheumatism Excellence (CARE)
                  address:
                     name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Padmanabha D. Shenoy
            url:http://orcid.org/0000-0002-7666-1361
            affiliation:
                  name:Centre for Arthritis & Rheumatism Excellence (CARE)
                  address:
                     name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Clinical Rheumatology
      issn:
         1434-9949
         0770-3198
      volumeNumber:38
Organization:
      name:Springer London
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Centre for Arthritis & Rheumatism Excellence (CARE)
      address:
         name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
         type:PostalAddress
      name:Centre for Arthritis & Rheumatism Excellence (CARE)
      address:
         name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
         type:PostalAddress
      name:Centre for Arthritis & Rheumatism Excellence (CARE)
      address:
         name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
         type:PostalAddress
      name:Centre for Arthritis & Rheumatism Excellence (CARE)
      address:
         name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Padmaja Raghavan
      affiliation:
            name:Centre for Arthritis & Rheumatism Excellence (CARE)
            address:
               name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
               type:PostalAddress
            type:Organization
      name:Sreelakshmi Sreenath
      affiliation:
            name:Centre for Arthritis & Rheumatism Excellence (CARE)
            address:
               name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
               type:PostalAddress
            type:Organization
      name:Somy Cherian
      affiliation:
            name:Centre for Arthritis & Rheumatism Excellence (CARE)
            address:
               name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
               type:PostalAddress
            type:Organization
      name:Padmanabha D. Shenoy
      url:http://orcid.org/0000-0002-7666-1361
      affiliation:
            name:Centre for Arthritis & Rheumatism Excellence (CARE)
            address:
               name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
      name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
      name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
      name:Centre for Arthritis & Rheumatism Excellence (CARE), Cochin, India
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(63)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.21s.

LINK . SPRINGER . COM {}